Login

Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

August 10, 2023
BioUtah News
August 10, 2023
BioUtah News
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

ComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments

August 3, 2023
BioUtah News
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease

August 3, 2023
BioUtah News
Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis […]

August 3, 2023
BioUtah News
Alucent Biomedical Wins FDA Approval for U.S. Clinical Study

U.S. FDA Grants an Investigational Device Exemption for Trial Evaluating Novel AlucentNVS Technology

August 3, 2023
BioUtah News
Quansys Biosciences and The Michael J. Fox Foundation Partner to Accelerate Parkinson’s Disease Research

Quansys Biosciences and The Michael J. Fox Foundation, announced a strategic partnership to accelerate research into PD.

August 2, 2023
BioUtah News
Government Price Setting Would Lead to Lost Therapies, Innovation and Jobs in Utah

New Study Details Proposed Federal Government-Mandated Drug Pricing Policies Senate SMART Prices Act Will Cost More Than 235 Fewer FDA Approvals Up To 23,000 Lost Jobs in Utah in Coming Decade SALT LAKE CITY, July 27, 2023 – Proposed expansions of federal government-mandated drug pricing policies present serious consequences for the development of and investment in […]

July 27, 2023
BioUtah News
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding […]

July 27, 2023
BioUtah News
DEVICE FOR TREATING CHALLENGING BONE FRACTURES CLEARED BY FDA

A new system for fixing bone fractures, called the Bone Bolt System, has been approved for market by the U.S. Food and Drug Administration (FDA), the University of Utah Orthopaedic Innovation Center (OIC), Department of Orthopaedics and Spencer Fox Eccles School of Medicine announced on July 20, 2023. “This achievement demonstrates the commitment by the […]

July 27, 2023
BioUtah News
Owlet Appoints Executive Jonathan Harris as New Company President and Chief Revenue Officer

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, today announces the appointment of executive Jonathan Harris as its new President and Chief Revenue Officer. Harris joins Owlet at a pivotal time in its business – one month after receiving clearance from the U.S. Food and Drug […]

July 27, 2023
Policy News
Bloom Surgical Awarded Competitive Grant from the NSF

Funding accelerates development of device for resolving visual disruptions in robotic procedures Salt Lake City, UT, June 1, 2023 – Bloom Surgical, Inc., a Utah-based surgical device startup, has been awarded a U.S. National Science Foundation Small Business Innovation Research grant for $256,000 to conduct research and development work on a novel micro-mechanical wiping mechanism […]

July 27, 2023
BioUtah News
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers. This comprehensive model is expected to identify more patients that could benefit from a change in their breast care.

July 27, 2023
BioUtah News
BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring, auto-identification, dose error reduction software and EMR interoperability BD Alaris™ Infusion System’s unique “One System” platform securely connects all patient modules to provide care teams […]

July 27, 2023
BioUtah News
Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally

July 20, 2023
Policy News
Rep. Moore Calls For Increased Transparency in the NCD Process

Utah U.S. Rep. Blake Moore (R-UT) signed onto a letter to HHS/CMS, led by House Ways and Means Committee Chair Jason Smith (R-MO) and House Energy and Commerce Committee Chair Kathy McMorris-Rodgers (R-WA), calling for increaed transparency in the NCD process following the agency’s recent release of the TCET notice. In part, the letter states, […]

July 20, 2023
BioUtah News
Owlet Appoints Healthcare Executive Melissa Gonzales to Board of Directors

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, is pleased to announce the addition of Melissa Gonzales to the Company’s Board of Directors. Gonzales brings more than 20 years of consumer and provider healthcare experience to Owlet, further advancing the Company as a leader in infant monitoring solutions. […]

July 20, 2023
BioUtah News
Co-Diagnostics, Inc. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx® Tech Program

The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY, July 13, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development […]

July 20, 2023
BioUtah News
Co-Diagnostics, Inc. Announces Recent Grant Awards

The Company intends to use funds awarded by the Bill & Melinda Gates Foundation toward completion of tuberculosis and HPV tests for its Co-Dx PCR Home™ platform  SALT LAKE CITY, July 18, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of […]

July 20, 2023
BioUtah News
ELEVAR THERAPEUTICS ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB AS A FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA

FORT LEE, NEW JERSEY, July 17, 2023 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. And a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the U.S. Food and Drug Administration (FDA) accepted a new drug application […]

July 20, 2023
BioUtah News
Stuart Goldblatt Joins CenExel as CEO

Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of Directors. Said Tom Wardle, “We are very excited to have a […]

July 13, 2023
BioUtah News
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today […]

July 13, 2023
BioUtah News
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as […]

July 13, 2023
BioUtah News
FDA Approves ARUP Laboratories’ AAV5 DetectCDx™, a First-Ever Companion Diagnostic Immunoassay for a Gene Therapy

SALT LAKE CITY—ARUP Laboratories today announced that the U.S. Food and Drug Administration (FDA) has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene therapy developed by BioMarin Pharmaceutical Inc., received contemporaneous FDA approval for the treatment of […]

July 13, 2023
BioUtah News
IONIQ is “Best Diagnostic Testing Solution 2023”

Salt Lake City, UT, July 7, 2023 –Medtech Breakthrough has awarded IONIQ Sciences the “Best Diagnostic Testing Solution of 2023″ (link). Our mission is to “break through” the screening status quo to catch cancer early. You and your doctor could know in just 20 minutes with no needles, no radiation, and no surgery. Watch this […]